Opendata, web and dolomites

Lumiblast SIGNED

A paradigm shift in cancer therapy – using mitochondria-powered chemiluminescence to non-invasively treat inaccessible tumours

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Lumiblast project word cloud

Explore the words cloud of the Lumiblast project. It provides you a very rough idea of what is the project "Lumiblast" about.

solid    aggressive    models    activated    tumors    eliminate    athens    scientific    lesion    inaccessible    polytechnic    activating    university    cell    cranium    group    cancers    headed    ltd    synthetic    lamp    chemistry    clinically    uoa    vougioukalakis    photochemistry    ros    oslo    renowned    mainly    treat    animal    photons    coming    sited    world    tissue    sources    tumour    limited    light    invasiveness    external    lumiblast    therapy    georgios    miranda    limitation    tumor    upv    agents    oslash    individual    margin    form    valencia    specialized    ceo    spread    knight    impressive    killing    miguel    hitherto    localized    collective    formulation    deep    photosensitive    incurable    penetration    record    sme    uio    hospital    luminescence    clinic    inside    ous    vision       multiforme    brain    act    invasive    resection    pdt    efficient    leader    nnensen    pharmaceutical    cultures    track    proof    practically    jan    hanne    origins    cells    breakthrough    photosensitizers    concerted    small    interdisciplinary    utilized    surgery    chemiluminescence    avoiding    photon    berg    completely    least    location    glioblastoma    gbm    photomedicine    photodynamic    usually    team    cm    expertise    nature    action    extracellular    treatments    ksl   

Project "Lumiblast" data sheet

The following table provides information about the project.

Coordinator
OSLO UNIVERSITETSSYKEHUS HF 

Organization address
address: KIRKEVEIEN 166 TARNBYGGET
city: OSLO
postcode: 450
website: http://www.oslo-universitetssykehus.no

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Project website http://www.lumiblast.eu
 Total cost 3˙031˙375 €
 EC max contribution 3˙031˙375 € (100%)
 Programme 1. H2020-EU.1.2.1. (FET Open)
 Code Call H2020-FETOPEN-2014-2015-RIA
 Funding Scheme RIA
 Starting year 2016
 Duration (year-month-day) from 2016-10-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OSLO UNIVERSITETSSYKEHUS HF NO (OSLO) coordinator 1˙306˙375.00
2    KNIGHT SCIENTIFIC LIMITED UK (PLYMOUTH DEVON) participant 477˙500.00
3    UNIVERSITAT POLITECNICA DE VALENCIA ES (VALENCIA) participant 424˙375.00
4    ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON EL (ATHINA) participant 413˙125.00
5    UNIVERSITETET I OSLO NO (OSLO) participant 410˙000.00

Map

 Project objective

Brain cancers such as glioblastoma multiforme (GBM) are practically incurable due to their location, invasiveness and highly aggressive nature. The use of light-based treatments of GBM by activating tumor-localized photosensitizers, such as in photodynamic therapy (PDT) has been clinically evaluated, but with limited success. This is mainly due to the limited penetration of light into tissue and the efficient spread of tumor cells typically up to at least 2 cm from the resection margin. Moreover, the existing photon based treatments (photodynamic therapy) are highly invasive and usually require open-cranium surgery, due to the need for external light sources. In the Lumiblast project the photons are produced inside the tumor cells in the form of chemiluminescence avoiding the major limitation of using external light to treat solid, deep-sited and inaccessible tumors. The principle utilized in Lumiblast may also be relevant for cancers of other origins. Due to its nature Lumiblast is expected to act on individual cells, rather than the collective lesion; it could thus completely eliminate the hitherto incurable GBM. Each GBM cell is expected to become a small lamp providing the light required for the photosensitive agents to become activated, killing the tumour cells from the inside. Lumiblast requires a concerted interdisciplinary action. The project coordinator (Berg’s group, Oslo University Hospital, OUS) is world renowned in PDT and photomedicine, while the team from the University of Athens (Georgios Vougioukalakis’ group, UoA) is up and coming with high expertise in synthetic chemistry. The Polytechnic University of Valencia (Miguel Miranda’s group, UPV) team is headed by a world leader in Photochemistry, the University of Oslo partner (Hanne H. Tønnensen’s group, UiO) is specialized in pharmaceutical formulation, and Knight Scientific Ltd (KSL, CEO Jan Knight) is an SME with an impressive track record in ROS-activated luminescence. This 4.5-year project will establish the Lumiblast breakthrough technology by providing proof-of-concept in extracellular systems, GBM cell cultures and animal models, with the vision to advance Lumiblast to the clinic 5-6 years after the end of the proposed project.

 Deliverables

List of deliverables.
Project website Websites, patent fillings, videos etc. 2019-05-31 16:51:01

Take a look to the deliverables list in detail:  detailed list of Lumiblast deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Pantelia, Daskalaki, Cuquerella, Rotas, Miranda, Vougioukalakis
Synthesis and Chemiluminescent Properties of Amino-Acylated luminol Derivatives Bearing Phosphonium Cations
published pages: 3957, ISSN: 1420-3049, DOI: 10.3390/molecules24213957
Molecules 24/21 2020-04-04
2020 Mantas Grigalavicius, Maria Mastrangelopoulou, Delmon Arous, Asta Juzeniene, Mathilde Ménard, Ellen Skarpen, Kristian Berg, Theodossis A. Theodossiou
Photodynamic efficacy of cercosporin in 3D tumor cell cultures
published pages: , ISSN: 0031-8655, DOI: 10.1111/php.13257
Photochemistry and Photobiology 2020-04-04
2019 Maria Mastrangelopoulou, Mantas Grigalavicius, Kristian Berg, Mathilde Ménard, Theodossis A. Theodossiou
Cytotoxic and Photocytotoxic Effects of Cercosporin on Human Tumor Cell Lines
published pages: 387-396, ISSN: 0031-8655, DOI: 10.1111/php.12997
Photochemistry and Photobiology 95/1 2019-04-18

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LUMIBLAST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LUMIBLAST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.2.1.)

RSENSE (2020)

Revolutionizing disease and environmental detection with portable optoacoustic sensing

Read More  

BRIEFING (2018)

Bridging the FET Innovation Gap

Read More  

ATEMPGRAD (2019)

Analysing Temperature Effects with a Mobile and Precise Gradient Device

Read More